Propanc Biopharma (PPCB) Net Income towards Common Stockholders (2010 - 2025)
Propanc Biopharma (PPCB) posted quarterly Net Income towards Common Stockholders of -$4.0 million for Q4 2025, down 835.33% year-over-year from $547186.7 in Q4 2024, and up 16.83% quarter-over-quarter from -$4.8 million in Q3 2025.
Propanc Biopharma (PPCB) Net Income towards Common Stockholders (2010 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Net Income towards Common Stockholders for 16 consecutive years, with -$4.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Income towards Common Stockholders fell 835.33% year-over-year to -$4.0 million; the TTM figure through Dec 2025 stood at -$67.0 million (down 3874.93% YoY), while the FY2025 annual figure was -$58.9 million, down 2826.43% from the prior year.
- Net Income towards Common Stockholders climbed to -$4.0 million in Q4 2025 per PPCB's latest filing, from -$4.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$354310.0 in Q3 2024 and bottomed at -$54.1 million in Q1 2025.
- Historically, Net Income towards Common Stockholders has averaged -$3.9 million across 5 years, with a median of -$752918.0 in 2022.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders soared 83.84% — and 2025, when it plunged 9866.33%.
- Propanc Biopharma's Net Income towards Common Stockholders stood at -$893375.0 in 2021, then jumped by 43.5% to -$504740.0 in 2022, then dropped by 22.63% to -$618969.0 in 2023, then soared by 30.5% to -$430183.0 in 2024, then sank by 835.33% to -$4.0 million in 2025.
- Business Quant data shows PPCB's Net Income towards Common Stockholders at -$4.0 million in Q4 2025, -$4.8 million in Q3 2025, and -$4.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | -4.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.02 Mn |
| Sep 30, 2025 | -4.84 Mn |
| Jun 30, 2025 | -4.07 Mn |
| Mar 31, 2025 | -54.07 Mn |
| Dec 31, 2024 | -430,183.00 |
| Sep 30, 2024 | -354,310.00 |
| Jun 30, 2024 | -358,578.00 |
| Mar 31, 2024 | -542,500.00 |
| Dec 31, 2023 | -618,969.00 |
| Sep 30, 2023 | -493,441.00 |
| Jun 30, 2023 | -805,760.00 |
| Mar 31, 2023 | -809,809.00 |
| Dec 31, 2022 | -504,740.00 |
| Sep 30, 2022 | -1.01 Mn |
| Jun 30, 2022 | -1.16 Mn |
| Mar 31, 2022 | -700,076.00 |
| Dec 31, 2021 | -893,375.00 |
| Sep 30, 2021 | -605,502.00 |
| Jun 30, 2021 | -1.17 Mn |
| Mar 31, 2021 | -417,738.00 |